OBI Pharma, Inc. today announced that the American Society of Clinical Oncology (ASCO) has formally accepted its abstract regarding the results of its Phase 2/3 study of OBI-822/821 (formerly OPT‐822/OPT‐821), which evaluated the clinical benefit and immunogenicity of the investigational immunotherapy in patients with metastatic breast cancer. Full results of the study will be presented as an oral presentation at ASCO’s 2016 Annual Meeting in Chicago, IL, USA, which is scheduled from 3-7 June 2016. The presenter will be Hope S. Rugo, MD, Professor of Medicine, Director, Breast Oncology and Clinical Trials Education, University of California San Francisco Helen Diller Family Comprehensive Cancer Center. The First Author of the abstract is Chiun‐Sheng Huang, MD, PhD, Professor of Surgery and Director of the Breast Center at the National Taiwan University Hospital.